ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa

Paris, April 27th, 2016 -  ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its abstract entitled, “Antiviral activity and safety of ABX464 in HIV-infected treatment-naïve patients” has been selected for presentation at the 21st International AIDS Conference (AIDS 2016) to be held in Durban, South Africa, 18-22 July 2016.  The date and time of the presentation will be communicated in the coming weeks.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41